Group 1 - The core viewpoint of the news is that Tianmu Pharmaceutical has shown a positive stock performance with a 3.52% increase year-to-date and a significant rise in revenue and net profit for the first nine months of 2025 [1][2] Group 2 - As of January 15, Tianmu Pharmaceutical's stock price was 17.92 CNY per share, with a market capitalization of 2.182 billion CNY and a trading volume of 21.8786 million CNY [1] - The company experienced a net inflow of main funds amounting to 299,600 CNY, with large orders accounting for 5.87% of total purchases [1] - The company's revenue for the first nine months of 2025 reached 159 million CNY, reflecting a year-on-year growth of 27.48%, while the net profit attributable to shareholders was 14.21 million CNY, up 484.48% year-on-year [2] Group 3 - Tianmu Pharmaceutical's main business revenue composition includes health products (48.01%), circulation goods (23.21%), raw materials (15.98%), traditional Chinese medicine (11.47%), Western medicine (0.89%), training (0.32%), and others (0.12%) [1] - The company has not distributed any dividends in the last three years, with a total payout of 59.6313 million CNY since its A-share listing [3]

Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.9% on December 29, with *ST Changyao leading the drop. The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1]. Group 1: Stock Performance - The following stocks in the traditional Chinese medicine sector showed notable performance: - WoHua Pharmaceutical (002107) closed at 6.33, up 2.43% with a trading volume of 106,100 shares and a transaction value of 65.58 million yuan [1]. - Tianmu Pharmaceutical (600671) closed at 17.39, up 1.81% with a trading volume of 22,600 shares and a transaction value of 39.17 million yuan [1]. - Weikang Pharmaceutical (300878) closed at 25.75, up 0.66% with a trading volume of 20,500 shares and a transaction value of 53.04 million yuan [1]. - Tongrentang (600085) closed at 32.46, up 0.65% with a trading volume of 168,300 shares and a transaction value of 221 million yuan [1]. - Yunnan Baiyao (000538) closed at 56.69, down 0.02% with a trading volume of 61,100 shares and a transaction value of 346 million yuan [1]. Group 2: Capital Flow - The traditional Chinese medicine sector saw a net outflow of 689 million yuan from institutional investors, while retail investors contributed a net inflow of 462 million yuan [2]. - Notable capital flows for specific stocks include: - Tongrentang (600085) had a net inflow of 28.03 million yuan from institutional investors, but a net outflow of 19.15 million yuan from retail investors [3]. - Wanbangde (002082) experienced a net inflow of 12.49 million yuan from institutional investors, with a net outflow of 9.44 million yuan from retail investors [3]. - Ma Yinglong (600993) had a net inflow of 5.11 million yuan from institutional investors, while retail investors saw a net inflow of 3.19 million yuan [3].

上海泽昌律师事务所 关于 杭州天目山药业股份有限公司 2025年第四次临时股东会的 法律意见书 上海市浦东新区向城路 288 号国华人寿金融大厦 1107A 室 电话：021-61913137 传真：021-61913139 邮编：200122 二〇二五年十二月 上海泽昌律师事务所 法律意见书 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东会所涉及的相关事项 进行了必要的核查和验证，核查了本所认为出具该法律意见书所需的相关文件、 资料，并出席参加了公司本次股东会的全过程。本所保证本法律意见书所认定的 事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误 导性陈述或者重大遗漏，并愿意承担相应法律责任。 鉴此，本所律师根据上述法律、法规、规章及规范性文件的要求，按照律师 行业公认的业务标准、道德规范和勤勉尽责精神，现出具法律意见如下： 一、 本次股东会召集人资格及召集、召开的程序 上海泽昌律师事务所 关于杭州天目山药业股份有限公司 2025 年第四次临 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-058 杭州天目山药业股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 12 月 22 日 (二) 股东会召开的地点：浙江省杭州市萧山区博亚时代中心 1803 会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 54,088,685 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 44.4154 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由董事会召集，董事长刘加勇先生主持，会议采用现场投票和网络 投票相结合的方式表决。本次会议的召集、召开及表决符合《公 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-057 杭州天目山药业股份有限公司 关于全资子公司收到药品再注册批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"）全资子公司黄山市天目 药业有限公司（以下简称"黄山天目"）于近日收到安徽省药品监督管理局核准 签发的《药品再注册批准通知书》。现将相关情况公告如下： 注：上述药品恢复生产时，须向安徽省药品监督管理局提出现场检查申请，并经其检查并抽验一批产品合格后，方可上市销售。 3 二、对公司的影响 上述药品《再注册批准通知书》的取得，保障了公司药品生产、销售资质的 稳定和延续，对公司后续的生产、销售、推广等具有积极的意义。公司将严格按 照要求开展药品生产工作，控制产品质量，持续为市场提供高品质的产品。 敬请广大投资者谨慎决策，注意投资风险。 特此公告。 1 | 序 | 产品 | 药品生 | 剂型 | 规格 | 药品 | 注册 | 药品注册 | 通知书编号 | 药品 批准文号 | | | --- | - ...

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]

杭州天目山药业股份有限公司 2025 年第四次临时股东会会议资料 杭州天目山药业股份有限公司 2025 年第四次临时股东会 会议资料 中国•杭州 二〇二五年十二月二十二日 1 / 5 杭州天目山药业股份有限公司 2025 年第四次临时股东会会议资料 目 录 | 2025 | 年第四次临时股东会会议议程 | 3 | | --- | --- | --- | | 2025 | 年第四次临时股东会须知 | 4 | | 议案一：关于续聘会计师事务所的议案 | | 5 | 2 / 5 杭州天目山药业股份有限公司 2025 年第四次临时股东会会议资料 2025年第四次临时股东会会议议程 会议召开方式：本次股东会采用现场会议和网络投票相结合的方式，网络投票系 统为上海证券交易所股东会网络投票系统 会议召集人：董事会 会议主持人：公司董事长 会议议程： 1.审议《关于续聘会计师事务所的议案》。 现场会议时间：2025年12月22日14:00 现场会议地点：浙江省杭州市博亚时代中心1803会议室 一、大会主持人介绍到会股东及来宾情况； 二、董事会秘书宣布到会股东代表资格情况； 三、董事会秘书宣读《2025 年第四次临时股东会会议 ...

Market Overview - The Shanghai Composite Index closed at 3889.35 points, with a change of 0.41% [1] - The total trading volume of A-shares reached 2119.01 billion yuan [1] Technical Analysis - 28 A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Hengfeng Information: -0.95% - Huaxia Happiness: -0.87% - Haitai New Light: -0.79% [1] Individual Stock Performance - Hengfeng Information (300605) saw a decline of 6.66% with a turnover rate of 18.06% [1] - Huaxia Happiness (600340) decreased by 1.63% with a turnover rate of 7.60% [1] - Haitai New Light (688677) increased by 1.19% with a turnover rate of 0.80% [1] - Jiangsu Beiren (688218) fell by 1.35% with a turnover rate of 3.68% [1] - Shenhui Technology (300853) decreased by 0.99% with a turnover rate of 2.24% [1] - Other notable declines include: - Zhongke Tongda (688038): -1.51% - Zhongke Information (300678): -0.37% - Fa Lion (605318): -0.91% [1] Additional Stock Movements - Stocks with minor declines include: - New Times (002527): -0.45% - Shanghai Environment (601200): -0.62% - Mind Electronics (300656): +0.29% [2] - The stock performance of various companies indicates a mixed market sentiment, with some stocks showing resilience while others face downward pressure [2]

Core Viewpoint - Tianmu Pharmaceutical announced the reappointment of Unitaizhenqing Accounting Firm (Special General Partnership) as the auditor for the company's financial report and internal control for the year 2025 [2] Group 1 - The company intends to continue its relationship with Unitaizhenqing Accounting Firm for auditing services [2] - The announcement was made on the evening of December 5 [2]

Core Viewpoint - Tianmu Pharmaceutical's stock issuance plan has automatically expired as the decision's validity period has lapsed, but this will not significantly impact the company's daily operations [1][2]. Group 1: Issuance Plan Details - Tianmu Pharmaceutical announced on December 5 that the resolution for its stock issuance plan has expired [1]. - The company had previously approved the stock issuance plan during meetings held on August 18, 2023, and December 6, 2023, with a validity period of 12 months from the latter date [1]. - A subsequent meeting on November 13, 2024, and a temporary shareholders' meeting on November 29, 2024, approved an extension of the resolution's validity period by another 12 months, now set to expire on December 5, 2025 [1]. Group 2: Future Financing Plans - Tianmu Pharmaceutical stated that the expiration of the issuance plan will not have a major impact on its daily operations [2]. - The company plans to develop capital market financing strategies based on its operational development needs and funding requirements in the future [2]. - Any new financing plans will adhere to relevant regulations and will involve necessary review procedures and information disclosure obligations [2].